Budesonid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Budesonid

Property Description
Active ingredient Budesonide
Pharmacological class Glucocorticoid (Corticosteroid)
Origin Synthetic steroid, non-halogenated
Forms Inhaled, nasal, oral (delayed-release), and rectal preparations
Primary action Potent anti-inflammatory and immunosuppressant

Budesonide: Core Identity and Pharmacological Classification

Budesonide is a powerful synthetic steroid that belongs to the glucocorticoid (corticosteroid) class of medicines, functioning as a primary anti-inflammatory agent and immunosuppressant. The substance is a non-halogenated steroid characterized by its high affinity for the glucocorticoid receptor. Clinically recognized for its potent local action, Budesonide is fundamentally designed to target inflammation directly within tissues rather than relying heavily on systemic distribution.

Composition and Forms: Strategic Delivery for Local Action

Budesonid’s single active ingredient is Budesonide, and it is available in a variety of pharmaceutical preparations designed for site-specific delivery. This substance is unique due to its formulation into multiple specialized forms, including inhalation suspension and powder inhaler for respiratory use, as well as specialized oral forms like delayed-release capsules. The principle behind this diverse formulation is to leverage a high degree of first-pass metabolism to minimize systemic exposure, thereby maximizing the local action of the active ingredient within the administered area.

General Purpose of Budesonide Therapy

The general purpose of Budesonide therapy is to provide effective, localized control over chronic inflammatory responses. By powerfully suppressing the activity of key immune cells, the drug reduces the release of inflammatory substances. This fundamental anti-inflammatory action is utilized to alleviate the irritation, swelling, and persistent inflammation associated with conditions requiring localized immune modulation, which is its distinctive therapeutic goal.

What side effects are possible with Budesonid?

Possible Side Effects and Safety Information

As a glucocorticoid, the official safety profile of Budesonide involves two main types of reactions: local effects related to the administration site and systemic effects linked to its steroid activity. The documented adverse reactions are categorized by the body system affected (System-Organ-Class or SOC) and their reporting frequency, as defined in regulatory labeling.

Common adverse reactions (affecting up to 1 in 10 people) generally include headache, gastrointestinal effects such as nausea and abdominal pain, and muscle cramps. For inhaled forms, oral candidiasis (thrush) is classified as a very common reaction. Effects on the respiratory system, such as pharyngitis and hoarseness (dysphonia), are also commonly documented.

Systemic Glucocorticoid Safety:

Long-term exposure or high systemic absorption poses a risk of serious reactions, which are uncommon or rare. These include signs of hypercorticism (e.g., Cushing's syndrome) and suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The risk of adrenal crisis is documented, particularly following abrupt cessation after prolonged high-dose use. Serious ocular effects, such as cataracts and glaucoma, are associated with long-term exposure.

Population and Exposure Constraints:

Regulatory documents highlight that the potential for delayed growth is a safety consideration for pediatric patients receiving chronic therapy. For all patients, impairment of liver function, specifically severe hepatic impairment, is noted as increasing the risk of systemic adverse effects. Co-administration with potent CYP3A4 inhibitors is also documented as increasing systemic exposure to Budesonide, thereby raising the risk of glucocorticoid-related effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Budesonide addresses the risks associated with chronic, excessive systemic exposure to the glucocorticoid. The documented manifestations of overexposure include clinical signs of hypercorticism, such as moon face, buffalo hump, easy bruising, acne, and skin striae. Overdose may also result in adrenal suppression, which can present with non-specific symptoms like tiredness, vomiting, weakness, and low blood pressure due to HPA axis suppression.

Life-threatening outcomes documented in regulatory guidance include the potential for acute adrenal suppression and anaphylaxis (severe allergic reaction). Patients must seek immediate medical attention for any signs of a severe hypersensitivity event, specifically difficulty breathing, hives, or swelling of the face, lips, tongue, or throat.

Management of overdose is generally limited to symptomatic and supportive treatment. For cases of chronic overexposure leading to systemic effects, regulatory procedures require the gradual dose reduction (tapering) of the medication. This procedure is mandated to allow the HPA axis to recover and prevent acute adrenal suppression. A specific antidote is not known. Patients with severe hepatic impairment are identified in labeling as a population with increased risk for hypercorticism due to heightened systemic drug exposure.

Therapeutic Uses of Budesonid

Main Uses and Benefits of Budesonid

Budesonid is a corticosteroid medication primarily used to manage various chronic inflammatory conditions. By acting locally at the site of inflammation, it helps reduce swelling, irritation, and tissue damage associated with overactive immune responses.

Respiratory Conditions

In the management of respiratory health, budesonid is frequently used for conditions characterized by airway inflammation:

  • Asthma: It is used as a maintenance treatment to prevent symptoms such as wheezing, shortness of breath, and coughing. It works by reducing the underlying inflammation in the bronchial tubes.
  • Allergic Rhinitis: When administered intranasally, it helps alleviate symptoms of seasonal or perennial allergies, including nasal congestion, sneezing, and itching.
  • Chronic Obstructive Pulmonary Disease (COPD): It may be used to reduce the frequency of exacerbations and improve overall lung function in individuals with chronic bronchitis or emphysema.

Gastrointestinal Disorders

Budesonid is also effective in treating inflammatory diseases of the digestive tract. Because it is designed to release in specific parts of the intestine and has a high rate of first-pass metabolism, it targets the gut while limiting systemic exposure.

  • Crohn’s Disease: It is often used to induce and maintain remission in mild to moderate cases, particularly those affecting the ileum or the ascending colon.
  • Ulcerative Colitis: It helps manage inflammation in the lining of the large intestine, reducing symptoms like abdominal pain and frequent bowel movements.
  • Eosinophilic Esophagitis: It may be used to treat inflammation in the esophagus caused by an accumulation of specific white blood cells, which can lead to difficulty swallowing.

Benefits of Localized Action

The primary benefit of budesonid is its high topical potency combined with low systemic availability. This means the medication focuses its anti-inflammatory effects where they are needed most—such as the lungs or the intestines—while minimizing the amount of the drug that circulates throughout the entire body.

Eligibility and Restrictions for Use

Budesonide is contraindicated in patients with known hypersensitivity to the drug or any component of the specific formulation. Inhaled forms must not be used for the immediate treatment of acute asthma episodes or status asthmaticus.

Age-Group Eligibility

Eligibility is strictly age- and formulation-dependent. Inhaled powder is typically approved for patients six years of age and older, while the inhalation suspension is indicated for children 12 months to eight years. Oral forms for inflammatory bowel diseases vary, approved for children eight years and older for Crohn’s disease, but certain ulcerative colitis tablets are indicated for adult use only.

Condition-Based Restrictions

Use is highly restricted in patients with impaired liver function: oral Budesonide is contraindicated or not recommended in cases of severe hepatic impairment or cirrhosis. Caution is explicitly mandated in regulatory labeling for patients with untreated systemic infections (such as active tuberculosis), hypertension, diabetes mellitus, glaucoma, or osteoporosis.

Pregnancy and Lactation

Use of systemically absorbed forms during pregnancy is restricted to situations where the clinical benefit justifies the potential risk. Inhaled and nasal forms are often considered lower risk. Budesonide is known to be excreted into human milk.

What should I know about interactions with other medicines?

Budesonide is metabolized primarily by the liver enzyme Cytochrome P450 3A4 (CYP3A4), and its systemic exposure is significantly increased when taken with strong inhibitors of this enzyme. This interaction can lead to elevated levels of budesonide in the body, increasing the risk of systemic corticosteroid side effects, such as hypercorticism and adrenal suppression.

Regulatory warnings advise against the co-administration of budesonide with potent CYP3A4 inhibitors. Specific medicines documented to cause this interaction include the antifungal ketoconazole, which has been shown to cause a several-fold increase in budesonide exposure. Other potent inhibitors listed in regulatory documents include itraconazole and certain HIV protease inhibitors like ritonavir.

It is also specified that grapefruit and grapefruit juice must be avoided during treatment. Grapefruit contains natural substances that inhibit the same CYP3A4 enzyme in the gut, which can approximately double the systemic absorption of oral budesonide.

Patients with moderate to severe hepatic impairment are also noted as being at higher risk for increased systemic exposure due to the reduced ability of the liver to clear the medicine. In patients transitioning from systemic corticosteroids, monitoring is advised to detect signs of steroid withdrawal.

Mechanism of Action

Molecular Agonism and Genomic Reprogramming

The mechanism begins with Budesonide acting as a full agonist at the intracellular Glucocorticoid Receptor (GR). This binding creates a complex that translocates to the cell nucleus, where it alters the cell’s genetic programming. The drug's action modulates gene transcription, leading to the inhibition of pro-inflammatory gene expression and the enhancement of anti-inflammatory protein synthesis by inhibiting factors like NF-kappaB and AP-1 (Transrepression) and promoting genes like annexin A1 (Transactivation).


Dampening Inflammatory Mediator Cascades

This genomic action directly suppresses key chemical signals. The mechanism includes inducing proteins like annexin A1, which indirectly blocks the enzyme Phospholipase A2 ( PLA2). This prevents the synthesis of inflammatory mediators such as prostaglandins and leukotrienes. This domain represents the molecular mechanism responsible for lowering the localized synthesis and secretion of inflammatory mediators.


️ Suppression of Immune Cell Activity

The resulting suppression of inflammatory gene products and chemical mediators affects immune cell function. The drug's mechanism reduces the activity, migration, and survival of inflammatory cells, including eosinophils and T-lymphocytes, at the site of administration. This results in decreased vascular hyperpermeability, reduced tissue exudate, and lower stimulation of mucus-producing cells in the affected organ.

Dosage and Administration Information

How Budesonide is Used in Clinical Practice

Budesonide is utilized through several distinct administration routes, which are matched to the specific condition being managed. These include oral, inhalation, rectal, and intranasal forms. The medicine’s use follows established clinical protocols, which involve precise dosing regimens, often centered around a once-daily or twice-daily schedule.

Official Usage Patterns

The most common oral use for conditions like active Crohn's disease and ulcerative colitis induction is typically 9 mg once daily for a specific period, often up to 8 weeks. For long-term conditions like IgA Nephropathy, the dose is 16 mg once daily for a duration of 9 months. Use for active disease is generally considered a short-term course with a required tapering process, or dose reduction, conducted before final discontinuation.

Administration Requirements

Standard usage protocols detail crucial procedural steps to ensure proper drug delivery:

  • Food Timing: For some oral forms, such as those used for IgA Nephropathy, administration must be at least one hour before a meal. Other specialized forms, like the oral suspension for Eosinophilic Esophagitis, require avoidance of all food and drink for 30 minutes after taking the dose.
  • Swallowing Integrity: Capsules and extended-release tablets must be swallowed whole and must not be crushed, chewed, or broken to preserve their modified-release profile.
  • Avoidance: The use of grapefruit and grapefruit juice must be avoided during the entire duration of oral therapy.
  • Missed Doses: If a dose is missed, standard practice involves taking the next regularly scheduled dose; the dose should not be doubled to compensate for the missed administration.

These instructions collectively define the standardized approach to the administration of Budesonide, ensuring the intended localized action of the medicine.

Recent Clinical Evidence

Evidence for use in Inflammatory Bowel Conditions (Crohn’s Disease and Ulcerative Colitis)

Randomized Controlled Trials (RCTs) were the primary research design used in studies examining Budesonide for inflammatory bowel conditions (IBD). These studies were used in research exploring how symptoms change over time in adults with active, mild to moderate Crohn’s disease localized to the ileum and/or ascending colon. Research also explored outcomes related to the return of symptoms over longer periods. Trials described patterns observed in the studies when measuring outcomes for clinical remission compared to placebo. For ulcerative colitis, trials studying specialized formulations described measured changes in clinical and endoscopic scoring. However, the evidence is limited regarding the ability to characterize long-term maintenance of clinical remission for Crohn’s disease. Studies explored comparative outcomes for remission against conventional systemic steroids, and findings were mixed.

Evidence for use in Chronic Asthma Maintenance

Research explored long-term, daily patterns of use for Budesonide in chronic asthma through large-scale, long-duration RCTs, including major research cohorts. Studies monitored outcomes related to systemic or functional imbalance, such as lung function parameters (e.g., FEV1). Research examined episodic or acute changes by monitoring outcomes related to the rate of asthma exacerbations and the reliance on rescue medication over extended time intervals. Studies reported patterns of measured changes in lung function parameters across the observed populations. Evidence for patients with uncontrolled or severe asthma remains insufficient compared to that available for those with mild-to-moderate disease.

What is Still Uncertain about Budesonide’s Research Base

The available evidence quality varies across studies, and data for certain groups remain insufficient. Long-term effects are not fully established for the sustained control of inflammation in several conditions, as follow-up durations were limited in many key trials. Comparative evidence is lacking for certain formulations and conditions. More research is needed to fully characterize long-term outcomes, especially regarding recurrence and maintenance.

Frequently Asked Questions (FAQ)

Common questions about Budesonid (FAQ)

Q: How quickly should I expect Budesonid to start working?

A: According to official product information, patients may start to notice improvement in their symptoms within 1 to 8 days after beginning treatment. However, it is noted that the full therapeutic benefit of the medicine may require several weeks, typically 4 to 6 weeks, of regular use to be fully realized.


Q: Is Budesonid the same as Fluticasone?

A: Budesonide and fluticasone are not the same; they are different chemical substances but both belong to the same pharmacological class, which is glucocorticoids. While they share a core mechanism of reducing inflammation, they are often delivered through different formulations and are indicated for treating different, specific conditions.


Q: What is the difference between Budesonid and other similar inhalers?

A: Official information indicates that Budesonide is a corticosteroid recognized for its high topical (local) anti-inflammatory activity. Its formulation is designed to minimize systemic absorption, meaning less of the medicine enters the bloodstream, which is achieved through high first-pass metabolism after it is administered.


Q: Can Budesonid cause weight gain?

A: Weight gain is documented in official safety information as a less common adverse reaction associated with the use of this medicine. This effect is described in greater detail within the product's safety information.


Q: Is it common to feel jittery or anxious after using Budesonid?

A: Adverse reactions related to mental health have been noted, with psychiatric disorders such as mood swings, nervousness, and difficulty sleeping (insomnia) being documented. These effects are typically associated with the systemic absorption of corticosteroids.


Q: Does Budesonid interact with pain relievers like ibuprofen?

A: Co-administration with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may potentially increase the risk of certain side effects in the gastrointestinal tract, including inflammation or bleeding. Official documents categorize this as a possible interaction based on the corticosteroid class.


Q: Does Budesonid affect blood sugar levels?

A: Official warnings advise caution for patients with pre-existing conditions like diabetes mellitus. This suggests a potential for the medicine to affect the body’s ability to regulate blood sugar, and this is noted due to its systemic steroid activity.


Q: Is it safe to use Budesonid during pregnancy?

A: Regulatory information indicates that the decision to use budesonide during pregnancy involves assessing whether the clinical benefit outweighs the potential risks. Official information notes that some formulations, such as inhaled types, have very low systemic absorption, potentially reducing exposure.


Q: What are the risks of using Budesonid while breastfeeding?

A: Data from the National Institutes of Health (NIH) indicates that only minute amounts of budesonide are typically detected in human breast milk when the mother is using the medicine. This usually results in negligible systemic exposure for the breastfed infant.


Q: Is Budesonid appropriate for older adults?

A: Regulatory documents do not establish a specific contraindication based on advanced age alone. However, official warnings mandate caution for all patients with moderate to severe hepatic (liver) impairment, as reduced liver function can increase the systemic exposure and risk of side effects.


Q: Can I stop taking Budesonid suddenly?

A: Official safety warnings indicate that abruptly stopping this medicine, especially after prolonged use, carries the risk of serious steroid withdrawal symptoms, including adrenal crisis. Dose reduction, often referred to as tapering, is typically mandated in official instructions prior to discontinuing the medicine.


Q: Why is Budesonid sometimes used in a nebulizer?

A: Budesonide is manufactured as an inhalation suspension specifically indicated for use with a nebulizer machine. This route of delivery is often specified for use in young children, typically aged 1 to 8 years, who may not be able to use other inhalation devices properly.


Q: Does Budesonid affect bone density with long-term use?

A: Official safety documents list the potential for adverse effects associated with prolonged use, including a risk of decreased bone mineral density, or osteoporosis. This is a recognized systemic risk associated with the long-term exposure to corticosteroids.


Q: Does Budesonid affect my sleep?

A: Difficulty sleeping or sleeplessness (insomnia) is listed among the documented side effects of this medicine. This is classified as a less common adverse reaction in the official safety profile.


Q: Is Budesonid effective for treating asthma attacks?

A: Formulations of Budesonide intended for chronic asthma management are explicitly contraindicated (not allowed) for the immediate relief of acute bronchospasm or status asthmaticus (asthma attacks). This medicine is designed for maintenance, not emergency use.


Q: Does Budesonid interact with alcohol?

A: While specific, quantified interactions between Budesonide and alcohol are generally not detailed on patient labels, regulatory warnings for this class of medicine often advise caution when using alcohol alongside prescribed medication.


Q: Can Budesonid cause changes in mood?

A: Official post-marketing data and safety information confirm that changes in mood and mood swings are documented adverse reactions that have been reported with the medicine.


Q: Is Budesonid used for stomach or gut issues?

A: Yes, specific oral formulations of Budesonide are approved for treating inflammatory bowel conditions, including active Crohn's disease and ulcerative colitis. These uses leverage the medicine’s local anti-inflammatory action in the gastrointestinal tract.


Q: What is the official purpose of Budesonid as described by regulators?

A: Regulators define the purpose of Budesonide through specific indications listed on the product label. These include the induction of clinical remission in conditions like mild to moderate active Crohn's disease and the long-term maintenance treatment of chronic asthma.


Q: Is there a certain time of day that Budesonid is usually recommended?

A: The recommended time of administration often depends on the formulation being used. For example, specific oral forms are often instructed to be taken once daily in the morning, while the optimal time for inhaled forms may vary based on the dosage schedule.


Q: Does Budesonid need to be taken with or without food?

A: Administration instructions are specific to the medicine's formulation. Some oral forms require the medicine to be taken at least one hour before a meal, while others require patients to avoid food and drink immediately after administration.


Q: Is a prescription required for Budesonid?

A: Budesonide is consistently categorized in official regulatory documents, such as the FDA Orange Book, as a prescription-only medicine (Rx) in all its approved formulations.


Q: Are there any known long-term complications from using Budesonid?

A: Potential long-term systemic risks documented for the medicine include serious effects such as cataracts, glaucoma, and HPA axis suppression (a disorder of the adrenal glands). These effects are associated with prolonged use.


Q: How does Budesonid impact the immune system?

A: As a glucocorticoid, the medicine works by suppressing the immune system’s inflammatory response. This action can potentially reduce the body's ability to fight off certain types of infection, which is a documented safety consideration.


Q: Is Budesonid listed as a controlled substance?

A: Budesonide is not listed as a controlled substance in the official regulatory schedules established by bodies like the U.S. Drug Enforcement Administration (DEA).


Q: Can Budesonid be used for non-respiratory problems like skin conditions?

A: Yes, Budesonide is a versatile glucocorticoid. In addition to asthma and rhinitis, it is used in the management of various inflammatory skin conditions, depending on the specific product formulation.


Q: Does Budesonid make you feel tired or drowsy?

A: Official safety information lists fatigue, or feeling tired, as a documented common adverse reaction. However, drowsiness is not specifically listed in the standard side effect profile.


Q: Is a dry mouth a common side effect of Budesonid?

A: Dry mouth is listed among the documented side effects of the medicine. It is typically classified as a less common adverse reaction in the official safety profile.


Q: What are the serious but rare side effects of Budesonid?

A: Serious documented risks include adrenal suppression, signs of hypercorticism (a disorder similar to Cushing's syndrome), cataracts, glaucoma, and an increased risk of severe infection. These effects are generally associated with long-term or high systemic exposure.

How should Budesonid be stored and disposed of?

The storage and disposal requirements for Budesonide are dictated by the specific product form to maintain stability.

Storage Conditions

Budesonide products must generally be stored at Controlled Room Temperature (20 C to 25 C). The inhalation suspension and nasal spray formulations must be protected from light and must not be frozen. Oral capsules should be stored in the original container and kept tightly closed to protect them from excess heat and moisture.

Stability and Handling

Inhalation ampules must remain in the sealed foil pouch until use. Ampules removed from the pouch must be used within two weeks, and the contents of an opened ampule must be used immediately and the remainder discarded. All Budesonide products must be stored out of the sight and reach of children.

Disposal

Unused or expired Budesonide should be disposed of according to the directions of a healthcare professional or pharmacist. Inhaler devices must be discarded after the labeled number of actuations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Budesonid found in:

A-Z Index: